Compare JBL & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JBL | TEVA |
|---|---|---|
| Founded | 1966 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.2B | 37.1B |
| IPO Year | 1998 | N/A |
| Metric | JBL | TEVA |
|---|---|---|
| Price | $300.45 | $32.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | ★ $272.33 | $38.63 |
| AVG Volume (30 Days) | 1.3M | ★ 5.1M |
| Earning Date | 06-16-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.01 | N/A |
| Revenue | ★ $25,282,320,000.00 | N/A |
| Revenue This Year | $15.81 | N/A |
| Revenue Next Year | $9.76 | $2.97 |
| P/E Ratio | $51.00 | ★ $28.19 |
| Revenue Growth | ★ 14.42 | N/A |
| 52 Week Low | $189.60 | $14.99 |
| 52 Week High | $428.93 | $37.35 |
| Indicator | JBL | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 31.78 | 42.35 |
| Support Level | $235.30 | $30.59 |
| Resistance Level | $378.54 | $32.40 |
| Average True Range (ATR) | 15.12 | 0.89 |
| MACD | -5.43 | -0.19 |
| Stochastic Oscillator | 10.90 | 18.14 |
Jabil Inc. is a U.S based company providing engineering, manufacturing, and supply chain solutions. It provides comprehensive electronics design, production, and product management services to companies in various industries and end markets. It operates through three segments: Regulated Industries, serving automotive, healthcare, and renewables; Intelligent Infrastructure, focused on AI, cloud, data centers, and communications, driving the majority of revenue; and Connected Living and Digital Commerce, specializing in digitalization and automation, such as robotics and warehouse automation. The company operates in the U.S., Mexico, China, Malaysia, Singapore, and several other markets.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.